Dr. James Stein, MD from the University of Wisconsin Medical School in Madison, praised the JUPITER study for exposing the fact that current therapeutic LDL-cholesterol levels are not only arbitrary, but are in fact a poor indicator of cardiovascular disease (CVD) risk. ?Most patients with heart attacks have normal cholesterol values,? he stated. With the cholesterol theory crumbling the industry is under intense pressure to come up with a new risk factor, and one that can be treated with the same statin drugs they have invested so much money in. Enter Dr. Ridker and C-reactive protein (CRP). Ridker has been pushing treating CRP with statins for years. But is CRP a risk factor? A National Panel on CRP found no evidence treating CRP levels will improve survival rates (www.urmc.rochester.edu/pr/News/story.cfm?id=182). Elevated CRP levels are associated with many things including; anger, stress, arthritis, cancer, lupus, pneumonia, TB, oral contraceptive use, pregnancy, heart attacks, surgery, trauma, intense exercise, etc. It?s a marker for disease, not the cause. But since statins lower CRP levels slightly, you can count on CRP becoming the new cholesterol. The public will be made to fear CRP, be tested for it, and be put on dangerous statins to lower it. What a racket.

A review of the literature by the Department of Medicine at the University of California, San Diego, cites nearly 900 studies which show adverse effect of statins, which are widely used in treating high cholesterol. Researchers report that muscle adverse effects are the most commonly reported problem in the literature and by patients. Adverse effects are dose dependent, and risks are amplified by drug interactions, thyroid disease, high blood pressure, diabetes and genetics.

The risk of adverse side effects goes up as age goes up, and this helps to explain why statins benefits have not been found to exceed their risks. Unfortunately, researchers report the physician awareness of statin side effects is low.

Statin side effects may include:
Increased cancer risk
Sexual dysfunction
Immune system suppresion
Cognitive loss
Neuropathy (numbness, tingling in extremities)
Anemia
Cataracts
Hepatic dysfunction.
Pancreatic dysfunction

American Journal of Cardiovascular Drugs